Loading clinical trials...
Loading clinical trials...
Lipid Management in Renal Transplant Recipients: A Pilot Study Evaluating the Use of PCSK-9 Inhibitor, Evolocumab.
Conditions
Interventions
Evolocumab
Statins (Cardiovascular Agents)
Locations
1
United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Start Date
February 17, 2021
Primary Completion Date
March 1, 2024
Completion Date
December 1, 2024
Last Updated
July 27, 2023
NCT06062394
NCT06903897
NCT06055036
NCT05802121
NCT05457582
NCT05015348
Lead Sponsor
Brigham and Women's Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions